MediPal Holdings Corporation
7459
Rangering i aksjer
#4253
Medipal Holdings Corporation, a Tokyo, Japan-based company founded in 1898,... Medipal Holdings Corporation, a Tokyo, Japan-based company founded in 1898, primarily specializes in the wholesale distribution of prescription pharmaceuticals throughout Japan. The firm procures a broad spectrum of healthcare products, including medical equipment, materials, and clinical diagnostic reagents, utilized across diagnostics, testing, treatment, and administration, often from the pre-symptomatic stage. It also offers contract-based post-marketing surveillance (PMS) services to manufacturers and strategically invests in products like orphan drugs. Beyond pharmaceuticals, Medipal Holdings diversifies its wholesale activities to encompass cosmetics, daily necessities, and over-the-counter medications. Its extensive product portfolio further includes animal health products for companion animals, raw materials for food processing in the agricultural, fisheries, and livestock sectors, along with livestock feed additives, various seasonings, veterinary medical equipment, packaging materials, and industrial chemicals. The company also provides a comprehensive suite of specialized services. These include conducting contract epidemiological and clinical studies, creating computerized databases for medical supplies and master product data for healthcare facilities, and offering health insurance claims reviews, medical coding dispatch, outsourcing, and remote education. Medipal's operations extend to life and non-life insurance agency services, cleaning management, the full management and operation of distribution centers, commissioned delivery, and worker dispatch. Additionally, it handles the planning, management, administration, and product/service development for its branded Class A health dispensing pharmacies. Serving an expansive client base, Medipal Holdings partners with hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company adopted its current name, Medipal Holdings Corporation in October 2009, having previously operated as Mediceo Paltac Holdings Co., Ltd.
Aksjekurs
$20.47
Markedsverdi
$3.73B
Endring (1 dag)
-0.57%
Endring (1 år)
23.25%
Land
JP
Handel MediPal Holdings Corporation (7459)
Kategori
Healthcare
P/E-forhold for MediPal Holdings Corporation (7459)
P/E-forhold per October 2026 TTM: 13.55
Ifølge MediPal Holdings Corporation sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 13.55. Ved slutten av 2024 hadde selskapet en P/E på 11.83.
P/E-forholdshistorikk for MediPal Holdings Corporation fra 2005 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 13.55 | 12.11% |
| 2025 | 12.09 | 2.20% |
| 2024 | 11.83 | 21.17% |
| 2023 | 9.76 | -32.12% |
| 2022 | 14.38 | -22.86% |
| 2021 | 18.64 | 62.38% |
| 2020 | 11.48 | -37.22% |
| 2019 | 18.28 | 29.27% |
| 2018 | 14.14 | 3.79% |
| 2017 | 13.63 | 3.92% |
| 2016 | 13.11 | -12.25% |
| 2015 | 14.94 | 6.79% |
| 2014 | 13.99 | -9.39% |
| 2013 | 15.44 | -28.55% |
| 2012 | 21.62 | -78.66% |
| 2011 | 101.31 | -23.98% |
| 2010 | 133.28 | 563.24% |
| 2009 | 20.09 | 32.62% |
| 2008 | 15.15 | -44.08% |
| 2007 | 27.10 | 41.90% |
| 2006 | 19.09 | -36.81% |
| 2005 | 30.21 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 26.02 | 91.98% |
US
|
|
| - | - |
US
|
|
| 34.08 | 151.42% |
US
|
|
| - | - |
US
|
|
| 45.62 | 236.56% |
AU
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.